Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...

--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business ...

Osaka: Takeda has announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...

Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process “The Board of ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...